It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

For Healthcare Professionals Outside the US

INDICATION

PLUVICTO® in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated
for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)
who have been treated with AR pathway inhibition and taxane-based chemotherapy.1

Learn How PLUVICTO® Works

PLUVICTO® is a PSMA-targeted radioligand therapy (RLT) that delivers DNA-breaking
radiation directly to PSMA-positive bone, nodal, and visceral metastases.1-4

PLUVICTO® targets PSMA-positive cells, including prostate cancer cells.1

See how PLUVICTO® works.

View VISION TRIAL Data

The VISION trial was a phase 3 prospective, multicentre, randomized, active-controlled, open-label study.
The trial enrolled 831 men who had PSMA-positive mCRPC with e.g. bone and/or soft tissue disease and had previously
received at least 1 androgen-receptor pathway inhibitor (ARPI) and 1 or 2 taxane-based regimens.5

The trial compared treatment with PLUVICTO® (7.4 GBq (200 mCi) once every 6 weeks for 4 to 6 doses) + best standard of care (BSoC; i.e., physician’s choice of ARPI, androgen-reducing agents, bone-targeted agents, radiation therapy, glucocorticoids, or others) vs. treatment with BSoC alone.5,6

 
Learn more about PSMA PET imaging with LOCAMETZ®
Learn more
Locametz Logo
References:
  1. PLUVICTO®. Summary of Product Characteristics. 2022.
  2. Boyd M, et al. Gene Ther. 1999 Jun;6(6):1147-52.
  3. Ruigrok EAM, et al. Eur J Nucl Med Mol Imaging. 2020;48(5):1339-1350.
  4. Fendler WP, et al. J Nucl Med. 2017;58(11):1786-1792.
  5. Sartor O, et al. N Engl J Med. 2021 Sep 16;385(12):1091-1103.
  6. Sartor O, et al. N Engl J Med. 2021 Sep 16;385(12):1091-1103. Supplementary Appendix.

This is a promotional international website for PLUVICTO® and is intended for healthcare professionals outside the US only. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for country specific information.

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC)